Publications

Sort by: Author [ Title  (Asc)] Type Year
A B C D E F G H I J K L M N [O] P Q R S T U V W X Y Z   [Show ALL]
O
Kourmentza, C., D. Araujo, C. Sevrin, C. Roma-Rodriques, J. Lia Ferreira, F. Freitas, M. Dionisio, P. V. Baptista, A. R. Fernandes, C. Grandfils, and M. A. M. Reis. "Occurrence of non-toxic bioemulsifiers during polyhydroxyalkanoate production by Pseudomonas strains valorizing crude glycerol by-product." Bioresour Technol 281 (2019): 31-40. AbstractWebsite

n/a

Veigas, Bruno, Pedro Pedrosa, Fabio F. Carlos, Liliana Mancio-Silva, Ana Rita Grosso, Elvira Fortunato, Maria M. Mota, and Pedro V. Baptista. "One nanoprobe, two pathogens: gold nanoprobes multiplexing for point-of-care." Journal of Nanobiotechnology 13 (2015). Abstract

n/a

Cordeiro, Mílton, Ana Rita Otrelo-Cardoso, Dmitri I. Svergun, Petr V. Konarev, João Carlos Lima, Teresa Santos-Silva, and Pedro Viana Baptista. "Optical and Structural Characterization of a Chronic Myeloid Leukemia DNA Biosensor." ACS Chemical BiologyACS Chemical Biology 13 (2018): 1235-1242. AbstractWebsite

n/a

Doria, Gonçalo, Bernhard G. Baumgartner, Ricardo Franco, and Pedro V. Baptista. "Optimizing Au-nanoprobes for specific sequence discrimination." Colloids Surf. B: Biointerfaces 77 (2010): 122-124.
Martins, Pedro, Mara Marques, Lidia Coito, Armando Pombeiro, Pedro V. Baptista, and Alexandra R. Fernandes. "Organometallic Compounds in Cancer Therapy: Past Lessons and Future Directions." ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 9 (2015). AbstractWebsite

Over the past few years, modern medicinal chemistry has evolved towards providing us new and alternative chemotherapeutic compounds with high cytotoxicity towards tumor cells, alongside with reduced side effects in cancer patients. Organometallic compounds and their unique physic-chemical properties typically used in homogenous catalysis are now being translated as potential candidates for medical purposes. Their structural diversity, ligand exchange, redox and catalytic properties make them promising drug candidates for cancer therapy. Over the last decade this area has witnessed a steady growth and a few organometallic compounds have in fact already entered clinical trials, emphasizing its increasing importance and clinical relevance. Here we intend to stress out the different applications of organometallic compounds in medicine with emphasis on cancer therapy, as well as address setbacks regarding formulation issues, systemic toxicity and off-target effects. Advantages over classical coordination metal complexes, their nanovectorisation and specific molecular targets are also discussed.